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Cardiac rehabilitation in cardiac
valve surgery patients: Beyond
cost-effectiveness
Ana Abreu
Life expectancy growth and progressively complex
therapeutic technique development are increasing
health costs, which reminds us that ﬁnancial resources
are not unlimited. The numbers of surgical and percu-
taneous procedures for valve replacement and repair
have been sharply rising, demanding an emergent eco-
nomic analysis of the preventive and therapeutic inter-
ventions involved. Nowadays, economic analysis of
health-related interventions is considered an important
tool for optimisation of resources and frequently
requested as essential to prove the real impact of inter-
ventions. Cardiac rehabilitation (CR) programmes, in
several studies and diﬀerent realities, have been demon-
strated to be cost-eﬀective in myocardial infarction and
heart failure,1 but this beneﬁt is not transferable to
heart valve surgery.
Despite the European Society of Cardiology (ESC)
and European Association of Preventive Cardiology
(EAPC) recommendations,2,3 CR in cardiovascular
disease and particularly in heart failure and valve dis-
ease, is markedly underused due to several barriers.4
Data regarding CR in valve disease are scarce,5 even
though CR has long been recommended for all patients
after heart valve surgery, especially for those with a
post-operative course complicated by heart failure.6
Recently, a Cochrane systematic review demonstrated
that exercise-based rehabilitation compared with no
exercise for adults after heart valve surgery, with or
without other interventions, may improve exercise
capacity.7 The authors considered that, due to the
lack of scientiﬁc evidence, further high quality rando-
mised clinical trials are needed in order to assess the
impact of exercise-based rehabilitation on patient-rele-
vant outcomes, including mortality, quality of life and
cost-eﬀectiveness analysis. This last outcome, cost-
eﬀectiveness, may be an important part of decision
making, a reason why CR programme directors need
to recognise and document the eﬃciency of their own
programmes.
Keeping in mind that economic health analyses are
always complex and very dependent on the target
patients, countries and considered costs, the results
obtained might be diﬀerent according to the evaluated
speciﬁc settings, always needing critical evaluation.
The present study8 approaches this very interesting
and important topic, since the cost-eﬀectiveness and
cost-utility analysis of CR in myocardial infarction
and in heart failure, as previously remarked, cannot
be extrapolated to valve surgery patients. This is the
ﬁrst CR cost-utility analysis in patients undergoing
heart valve surgery and followed for six months, from
the CopenHeartVR trial.9 It has the strength to include
patient randomisation instead of gathering a CR cohort
without a control group and to provide rather complete
information on multiple costs, namely those which are
patient-borne (transportation expenses and time spent
on transportation and CR).
Several limitations are present in this study:
. The sample dimension is not large for this kind of
analysis (147 patients) and includes a rather hetero-
geneous group of patients, with diﬀerent aﬀected
valves, diﬀerent pathologies and diﬀerent aetiolo-
gies. The original recruitment target number of
patients (210 patients) was not attained in the
CopenHeartVR trial, though power was recalculated
for the obtained sample. A minor gender imbalance
was observed (11% more males in the CR group).
The limited number of patients in the study did not
allow separate sub-analysis of CR in the diﬀerent
settings. Results of cost-utility analysis might be dif-
ferent in old patients with degenerative aortic valve
disease and multiple co-morbidities and in young
patients with mitral valve prolapse and regurgitation
or with pulmonary stenosis.
. This is a selected group of valve patients indicated
for surgery with low surgical risk by Euroscore II
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(mean value 1%), good left ventricular ejection frac-
tion (LVEF) (mean value 55% and 54%, for CR and
control), New York Heart Association (NYHA)
class <3 (74% and 69% of patients, for CR and
control), mostly in sinus rhythm, with few diabetics
and high educational level. More severe high-risk
patients would probably lead to diﬀerent results.
. The conclusions of the study must be restricted to
the sample of operated valve Danish patients, which
means that the results cannot be automatically
assumed in other countries being the economic
health analysis very dependent on the study popula-
tion, as previously mentioned.
. Also, home-based CR should not be mixed with
centre-based CR. Of the patients, 69% received a
controlled rehabilitation programme and the others
had home-based or self-training in a ﬁtness centre.
Diﬀerent CR types should be evaluated diﬀerently.
Also, separate analysis of diﬀerent subsets is limited
by the sample size. In this study, it is not possible to
tell if the involved modalities may have inﬂuenced
the analysis results.
. Cost-utility analysis, which was used in the present
paper,8 has its own strengths and limitations. The
unit of health used, quality adjusted life years
(QALYs), is a measure which is more health and
well-being related than a single natural unit (as
years of life lost). QALYs assume that the only poten-
tial beneﬁt from healthcare is the improvement in
heart-related quality of life (HRQL). Diﬀerent coun-
tries with diﬀerent patterns of healthcare delivery and
therefore diﬀerent costs may have diﬀerent results.
This study, with the described limitations, did not
conﬁrm statistical diﬀerences in HRQL, or in societal
costs between both groups (CR and no CR) in this
sample of patients. However, it showed a tendency
towards cost savings, which may need to be conﬁrmed
in future studies with a larger homogeneous higher risk
population, like older patients with aortic stenosis (a
growing population segment) submitted to valve
replacement with a well-deﬁned CR programme, uni-
form in modality.
Despite the importance of economic analysis, doctors
need to continue treating patients in the best way pos-
sible. Many of these surgical valve patients are severely
deconditioned by previous auto-limitation of functional
activities due to symptoms. Especially in older heart
failure patients, daily life capacities are progressively
limited, decreasing daily life activities, independence
and quality of life. For most patients, enhanced func-
tional capacity leads to a greater ability to perform the
activities of daily living and to tolerate longer periods of
activity with less perceived exertion.10 Before aortic
valve replacement, many patients are classiﬁed in class
III or IV NYHA11,12 and the average improvement after
surgery at six months without CR is one class.11–14
Abnormal rest and exercise cardiac haemodynamics per-
sist for 6–12 months after surgery.13 The exercise
training component of CR is useful for reversing the
symptoms associated with deconditioning. After aortic
valve replacement, the increase in aerobic capacity can
be 38% higher at six months and 37% higher at 12
months in exercise training patients compared to
patients without CR.15 Besides functional aerobic
training in the exercise programme, ﬂexibility, equilib-
rium and strength training are considered fundamental.
These patients also need, besides the functional com-
ponent of CR, all other components, like medical
management and, no less important, education regard-
ing safety and risks of physical activity, symptom
monitoring, nutrition information, comorbidity
treatment, risk factors control and adherence to medi-
cation (such as anticoagulation in mechanical prosthetic
valves and in atrial ﬁbrillation). Older surgical valve
patients, with longer hospital admissions andmore com-
plications, namely atrial ﬁbrillation,16 are a particular
group requiring comprehensive multidisciplinary CR.
The clinical reason for CR is to treat the patient after
surgery, to optimise his physical and psychological
status, while the reason for surgery is to treat the diseased
valve, repairing it or implanting a new one. So, the target
of surgery is the valve and the target of CR is the patient.
Some questions remain:
. If we can improve a patient’s functional, psycho-
logical or independence status with CR, which is
certainly less expensive than most interventions
with devices, why should we leave a patient only
partially treated by cardiac surgery?
. If a valve is implanted and the patient still needs to
remain in bed, depending on someone for daily life
activities, because of muscle atrophy and loss of
strength, joints stiﬀness, risk of falls and depression
can we consider this intervention a therapeutic success?
. And if we want to consider health costs, are all costs
included in the economic health analysis at long-term,
like patient long-duration incapacity to work or early
retirement, frequent work absence of family members
to support the patient, more medication needed
(namely antidepressants or benzodiazepines), loss of
independence and complications of immobilisation?
This paper,8 maybe due to several limitations, does
not absolutely prove cost-utility of CR in this analysis in
a small and heterogeneous sample of low-risk patients
from Denmark, but proves that there is no economic
cost-utility advantage regarding not performing CR.
Even more, despite not having improved HRQL, it
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shows a positive tendency in cost savings, suggesting the
likelihood of CR being cost-eﬀective to society, out-
weighing the extra costs of CR, as the authors conclude.
Based on the best clinical practice, I would prefer to
consider that CR should not be restricted by the cost-
utility analysis results demonstrated in this study. With
all the already proven and expected beneﬁts of CR in
these patients, the intervention would have to be eco-
nomically disastrous (which it was not) for not being
provided to all operated valve patients. It must be
stressed that this study does not change that all valve
patients operated who are stable and have no clear
contra-indications should perform CR, with a tailored
programme, identical to heart failure programmes, with
conﬁrmed beneﬁts but adjusted, especially for those
who can get the greatest gains, like the old, frail,
dependent, functionally limited, obese, with several
comorbidities or with heart failure patients.
A larger economic study will probably demonstrate,
in diﬀerent groups of valve disease patients, the bene-
ﬁcial cost-eﬀectiveness of CR after surgery and this
might be important for those who are not completely
convinced by the positive clinical and social impact of
this essential intervention. Even more, the analysis and
evaluation of results should take into account that
some costs (dependence, depression, disability) have
not been considered in the economic analysis and
might be the greatest.
At this point, we may ask ourselves, as Joep Perck16
did before for coronary disease: Does CR need to be
cost-eﬀective? Is there a better alternative?
I do not think so. Since we do need CR in these
patients, our eﬀorts should be applied, not in
evaluating the cost-utility of CR in valve disease
patients, but in evaluating which speciﬁc programme
or protocol is more cost-eﬀective, including the forgot-
ten social, familiar and personal costs, in these particular
patients. The same way a surgeon considers, when valve
surgery is indicated to a patient, not if the valve needs to
be cost-eﬀective, but which is the best valve to implant.
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